← Back to Screener
Trevi Therapeutics, Inc. Common Stock (TRVI)
Price$15.40
Favorite Metrics
Price vs S&P 500 (26W)43.71%
Price vs S&P 500 (4W)34.05%
Market Capitalization$1.96B
All Metrics
Book Value / Share (Quarterly)$1.43
P/TBV (Annual)1.67x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)17.51%
EPS (TTM)$-0.32
10-Day Avg Trading Volume1.78M
EPS Excl Extra (TTM)$-0.32
EPS (Annual)$-0.32
ROI (Annual)-23.33%
Cash / Share (Quarterly)$1.47
ROA (Last FY)-22.10%
EBITD / Share (TTM)$-0.37
ROE (5Y Avg)-66.44%
Cash Flow / Share (Annual)$-0.33
P/B Ratio10.67x
P/B Ratio (Quarterly)8.76x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-29.59x
ROA (TTM)-24.15%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)19.66x
Quick Ratio (Quarterly)19.53x
3-Month Avg Trading Volume1.52M
52-Week Price Return149.67%
Tangible BV / Share (Quarterly)$1.79
52-Week High$15.76
EPS Excl Extra (Annual)$-0.32
CapEx CAGR (5Y)-16.74%
Tangible BV CAGR (5Y)48.70%
26-Week Price Return52.45%
Quick Ratio (Annual)19.53x
13-Week Price Return33.13%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.66x
Enterprise Value$1,936.577
Book Value / Share Growth (5Y)-0.65%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.47
3-Month Return Std Dev61.60%
Net Income / Employee (TTM)$-2
ROE (Last FY)-23.33%
Net Interest Coverage (Annual)-27.08x
EPS Basic Excl Extra (Annual)$-0.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.32
ROI (TTM)-25.49%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.79
Price vs S&P 500 (52W)114.58%
Year-to-Date Return21.65%
5-Day Price Return14.25%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-41.93%
Month-to-Date Return27.66%
Cash Flow / Share (TTM)$-0.57
EBITD / Share (Annual)$-0.37
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-47.72%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)1.67x
P/B Ratio (Annual)8.76x
Book Value / Share (Annual)$1.43
Price vs S&P 500 (13W)30.26%
Beta1.13x
ROE (TTM)-25.49%
52-Week Low$5.38
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.28
4.28
4.28
4.28
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TRVITrevi Therapeutics, Inc. Common Stock | — | — | — | — | $15.40 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine. The company is advancing Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis and other chronic cough indications, as well as for prurigo nodularis. Haduvio represents a novel therapeutic approach for these underserved patient populations.